

Extrahuman Epidemiology of *Acinetobacter baumannii* in Lebanon

Rayane Rafei,^{a,b} Monzer Hamze,^b Hélène Pailhoriès,^{a,c} Matthieu Eveillard,^{a,c} Laurent Marsollier,^d Marie-Laure Joly-Guillou,^{a,c} Fouad Dabboussi,^b Marie Kempf^{a,c}

L'UNAM Université, Université d'Angers, Groupe d'Etude des Interactions Hôte-Pathogène, UPRES EA3142, Institut de Biologie en Santé-IRIS, CHU, Angers, France^a; Laboratoire Microbiologie Santé et Environnement (LMSE), Centre AZM pour la Recherche en Biotechnologie et Ses Applications, Université Libanaise, Tripoli, Lebanon^b; Laboratoire de Bactériologie, Institut de Biologie en Santé-PBH, CHU, Angers, France^c; ATOMycA, INSERM Avenir Team, CRCNA, INSERM U892, 6299 CNRS and l'UNAM, CHU and Université d'Angers, Angers, France^d

The presence of *Acinetobacter baumannii* outside hospitals is still a controversial issue. The objective of our study was to explore the extrahospital epidemiology of *A. baumannii* in Lebanon. From February 2012 to October 2013, a total of 73 water samples, 51 soil samples, 37 raw cow milk samples, 50 cow meat samples, 7 raw cheese samples, and 379 animal samples were analyzed by cultural methods for the presence of *A. baumannii*. Species identification was performed by *rpoB* gene sequencing. Antibiotic susceptibility was investigated, and the *A. baumannii* population was studied by two genotyping approaches: multilocus sequence typing (MLST) and *bla*_{OXA-51} sequence-based typing (SBT). *A. baumannii* was detected in 6.9% of water samples, 2.7% of milk samples, 8.0% of meat samples, 14.3% of cheese samples, and 7.7% of animal samples. All isolates showed a susceptible phenotype against most of the antibiotics tested and lacked carbapenemase-encoding genes, except one that harbored a *bla*_{OXA-143} gene. MLST analysis revealed the presence of 36 sequence types (STs), among which 24 were novel STs reported for the first time in this study. *bla*_{OXA-51} SBT showed the presence of 34 variants, among which 21 were novel and all were isolated from animal origins. Finally, 30 isolates had new partial *rpoB* sequences and were considered putative new *Acinetobacter* species. In conclusion, animals can be a potential reservoir for *A. baumannii* and the dissemination of new emerging carbapenemases. The roles of the novel animal clones identified in community-acquired infections should be investigated.

Acinetobacter baumannii is an opportunistic pathogen involved in a large number of hospital-acquired infections and associated with increased mortality and morbidity (1). One of the main reasons for the current increased interest in *A. baumannii* is its remarkable ability to acquire mechanisms of resistance to almost all available antimicrobial agents, including carbapenems (1–3). Genotyping approaches have attributed its global spread to a limited number of successful clones responsible for the majority of the worldwide nosocomial outbreaks (4–6). Among them, international clones 1 and 2 have been extensively disseminated in more than 30 countries (2).

Despite the fact that the hospital ecology of the bacterium has been intensively studied, its ecology outside hospitals remains unclear and is the subject of great debate (7–9). Difficulties regarding *A. baumannii* identification methods enhance this ambiguity (9). *A. baumannii* can cause severe community-acquired pneumonia occurring mainly during the warm and humid months in tropical and subtropical zones (10, 11). In addition, *A. baumannii* isolates have been recovered from wounds of survivors of natural disasters (12, 13), as well as from soldiers (14) and civilians (15) during warfare. Reports studying *A. baumannii* human carriage in the community are rare, and the prevalence has varied according to the countries and the identification methods used, from 0.5% to 3% in Europe (16–18), 4% in Hong Kong (19), and 5.4% in Senegal (20) to 10.4% in the United States (21). *A. baumannii* was also found in environments such as soil (22, 23) and water (24, 25) and in food products, such as vegetables (22, 26), fish, meat (22), and raw bulk tank milk (27). Finally, in animals, the bacterium has been described as an emerging pathogen in veterinary clinics in Germany (28) and Switzerland (29). It was also involved in asymptomatic carriage in some animals (20, 30, 31). Moreover, its presence was reported worldwide in human body and head lice (20, 32–34), as well as in arthropods (35).

Unlike clinical strains, there are limited reports using genotyping methods to explore the extrahospital epidemiology of *A. baumannii* (20–22, 30, 31, 33, 36, 37). In Lebanon, only strains belonging to a clinical context have been studied (15, 38–40), and no data concerning the occurrence of *A. baumannii* outside Lebanese hospitals are available. The aim of this study was to look for the presence of *A. baumannii* in different environments, to study its susceptibility to antibiotics, and to characterize the predominant community genotypes by using two genotyping approaches: multilocus sequence typing (MLST) and *bla*_{OXA-51} sequence-based typing (SBT).

MATERIALS AND METHODS

Sample collection and cultivation. Sampling was performed from February 2012 to October 2013 from soil, animals, and food products in different regions of Lebanon (Fig. 1). The majority of samples were taken from two regions in North Lebanon: Tripoli, the second-largest city of the country after Beirut, and Akkar, which is a rural district.

Fifty-one soil samples were collected in urban and agricultural zones. They were suspended in water at 10%, vortexed for 15 min to fully homogenize the suspension, and then decanted for 30 min. Fifty

Received 25 November 2014 Accepted 11 January 2015

Accepted manuscript posted online 23 January 2015

Citation Rafei R, Hamze M, Pailhoriès H, Eveillard M, Marsollier L, Joly-Guillou M-L, Dabboussi F, Kempf M. 2015. Extrahuman epidemiology of *Acinetobacter baumannii* in Lebanon. *Appl Environ Microbiol* 81:2359–2367. doi:10.1128/AEM.03824-14.

Editor: G. T. Macfarlane

Address correspondence to Marie Kempf, makempf@chu-angers.fr.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AEM.03824-14




FIG 1 Map of Lebanon showing the distribution of epidemiological samples between districts. E, environmental samples (soil and water); A, animal samples; F, food samples (meat, milk, and cheese).

minced meat and seven raw cheese samples, purchased from butchers and shops, were cut aseptically into very small pieces and homogenized by using a stomacher bag (Interscience, Saint Nom, France) and then suspended at 10% in sterile water. Seventy-three water samples and 37 raw cow milk samples were also collected. Finally, 379 samples from different animals recovered from fecal specimens or from rectum and/or mouth swabbing were collected. Feces were collected directly after defecation or from the cow anus to limit contamination with soil or any other sources and suspended in water at 10%. Consent was given orally by the farmers.

For all the samples except the rectal swabs, 5 ml was added to 20 ml of Baumann medium (41), a minimum enrichment medium with acetate as the sole carbon source. The swabs were directly discharged in 20 ml of Baumann medium. Samples were then mixed on a rotor shaker at 200 rpm for 48 h at 37°C, and cultures were streaked on MacConkey agar with cephadrine (40 mg/liter), amoxicillin (10 mg/liter), fosfomycin (30 mg/liter), and cycloheximide (400 g/liter) and incubated at 37°C for 48 h. In addition, 12 isolates identified as *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex and stored in the collection of the AZM Center for Research in Biotechnology and Its Application were incorporated in this study. They were recovered from raw cheese and lettuce.

Bacterial identification. Uncolored colonies grown on MacConkey agar were selected for further identification. Genus *Acinetobacter* identification was presumptively performed on the basis of Gram staining, a negative oxidase test, and a Vitek MS (bioMérieux, Marcy l'Étoile, France) test. Identification was further confirmed by partial sequencing of the *rpoB* gene (42).

Susceptibility testing and Investigation of carbapenemase-encoding genes. Antibiotic susceptibility testing was performed by the disc diffusion method according to the guidelines of the French Comité de l'Antibiogramme de la Société Française de Microbiologie ([http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFM_EUCAST_V1_0_2014\(1\).pdf](http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFM_EUCAST_V1_0_2014(1).pdf)). The antibiotics tested were ticarcillin, piperacillin plus tazobactam, ceftazidime, imipenem, ciprofloxacin, amikacin, gentamicin, tobramycin, co-trimoxazole, colistin, netilmicin, doxycycline, and rifampin. Resistance to carbapenem was confirmed by determining the MICs of imipenem, meropenem, and doripenem with Etest strips (bioMérieux, Marcy l'Étoile, France). All identified *A. baumannii* isolates were investigated by PCR assays for the presence of the carbapenemase-encoding genes *bla*_{OXA-23} (43), *bla*_{OXA-24} (43), *bla*_{OXA-58} (43), and *bla*_{OXA-143} (44) and the insertion sequence *ISAbal* (45).

Genotyping. Genotyping by MLST and *bla*_{OXA-51} SBT was performed on all identified *A. baumannii* isolates. MLST was done according to the Pasteur scheme (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html>). The bacterial population was analyzed with eBURST (46) (on data available as of 8 July 2014), and when possible, isolates were assigned to their clonal complexes (CC), which are defined as the founder sequence type (ST) and its single-locus variants (SLV) (5). The full length of the *bla*_{OXA-51} gene (825 bp) was amplified and sequenced with the external primers OXA-69A/OXA-69B as described by Hamouda et al. (47). The sequences were compared to those of all variants present in BLAST. New variants were submitted to GenBank and the Lahey database for beta-lactamase classification (<http://www.lahey.org/studies/webt.asp>). Moreover, 24 new STs have been assigned by MLST Pasteur: ST286 to ST296 and ST464 to ST476.

Nucleotide sequence accession numbers. Twenty-one nucleotide sequences of *bla*_{OXA-51} genes were submitted to GenBank with the following accession numbers: KF048909 to KF048919 and KJ584916 to KJ584925.

RESULTS

Bacterial identification. A total of 597 samples were analyzed. The 12 *Acinetobacter* strains stored in the collection of the AZM Center were also incorporated. Overall, 161 *Acinetobacter* species isolates were isolated, and among them, 42 were identified as *A. baumannii* by *rpoB* gene sequencing. Table 1 shows the distribution of the identified *Acinetobacter* species according to the sources of the samples. Briefly, no *A. baumannii* isolate was identified in soil samples. Most of the isolates were isolated from animals. Moreover, 30 isolates had new partial *rpoB* sequences and were considered putative new *Acinetobacter* species.

Antimicrobial susceptibility testing results for *A. baumannii*. The 42 *A. baumannii* isolates identified showed a susceptible phenotype in response to most of the antibiotics tested. Two isolates were intermediate to rifampin, and one isolate was resistant to ciprofloxacin and doxycycline. Only one isolate showed resistance to carbapenems. It was isolated from a horse's mouth and was susceptible to imipenem (MIC = 2 mg/liter), intermediate to meropenem (MIC = 4 mg/liter), and resistant to doripenem (MIC = 4 mg/liter). The *bla*_{OXA-143} gene was detected by PCR and confirmed by sequencing. The insertion sequence *ISAbal* was present in only two isolates from cats.

As for the other *Acinetobacter* sp. isolates, most were wild type, and few isolates exhibited resistance to co-trimoxazole, ciprofloxacin, doxycycline, and rifampin. Only one showed carbapenem resistance. It was identified as *Acinetobacter pittii* and was isolated from a rabbit's mouth. It showed high MICs of imipenem (16 mg/liter), meropenem (>32 mg/liter), and doripenem (>32 mg/liter) and was an OXA-24-producing isolate.

MLST analysis. MLST was performed on all 42 identified *A. baumannii* isolates (Table 2). The isolates were grouped into 36 different STs, and among them, 30 were found in a single isolate. Twenty-four STs were new and reported for the first time in this study: 9 had new allelic combinations of previously known alleles (ST286 to ST288, ST293, ST464, and ST469 to ST472), and 15 had new alleles, leading to a new allelic profile (ST289 to ST292, ST294 to ST296, ST465 to ST468, and ST473 to ST476). The relationship of the STs in this study and the existing STs was studied by eBURST (Fig. 2). Some detected STs belonged to clonal complexes, such as ST1 (the founder of CC1), ST216 (the founder of CC216), ST10 (the founder of CC10), ST138 and ST193 (belonging to CC33), and ST464 (belonging to CC85). Other STs shared

TABLE 1 Distribution of the identified *Acinetobacter* species according to the sources of samples

<i>Acinetobacter</i> species isolated	Total no. of isolates	Environmental isolates		Food isolates		Animal isolates	
		Source	No. of isolates found	Source	No. of isolates found	Source	No. of isolates found
<i>A. baumannii</i>	42	Water	5	Cheese	2	Cow	17
				Meat	4	Cat	2
				Milk	1	Horse	1
						Goat	3
						Dog	3
						Rabbit	1
						Donkey	1
						Mule	1
						Chicken	1
<i>A. pittii</i>	61	Water	8	Cheese	6	Cow	14
		Soil	7	Lettuce	4	Horse	4
				Meat	6	Goat	2
						Dog	6
						Sheep	2
						Rabbit	1
						Chicken	1
<i>A. calcoaceticus</i>	4	Soil	1	Lettuce	1	Goat	2
<i>A. bereziniae</i>	10			Meat	3	Cow	4
						Horse	1
						Dog	1
						Pigeon	1
<i>A. johnsonii</i>	1					Rabbit	1
<i>A. lwoffii</i>	1					Cat	1
<i>A. schindleri</i>	3					Cat	3
<i>A. radioresistens</i>	1					Cat	1
<i>A. beijerinckii</i>	1					Cow	1
<i>A. junii</i>	1					Cat	1
<i>A. soli</i>	1			Lettuce	1		
<i>A. gernerii</i>	1					Goat	1
Gen. sp. 15 TU ^a	4					Cow	2
						Cat	1
						Dog	1
Putative novel <i>Acinetobacter</i> species	30	Soil	1	Meat	1	Cow	20
						Horse	2
						Dog	1
						Sheep	3
						Goose	1
						Pig	1
Total	161		22		29		110

^a Gen. sp., genomic species.

similarities with known STs: ST46 with ST149, ST108 with ST112, ST221 with ST133, ST250 with ST188, and ST472 with ST439. The remaining identified STs (ST13, ST286 to ST296, ST465 to ST471, and ST473 to ST476) were singletons, and no ST similar to them has been characterized yet.

bla_{OXA-51} SBT analysis. The full-length sequence analysis of the *bla_{OXA-51}* genes of the 42 *A. baumannii* isolates revealed the presence of 34 gene variants, and among them, 26 were singletons and 21 had not been described before (GenBank accession numbers [KF048909](#) to [KF048919](#) and [KJ584916](#) to [KJ584925](#); Lahey numbers OXA-338 to OXA-346 and OXA-407 to OXA-413) (Table 2 and Fig. 3). These 34 *bla_{OXA-51}* gene variants coded for 31 OXA protein variants, with 16 being new ones (Fig. 3). Figure 4 shows an alignment of the full amino acid sequences of these new enzymes. It should be noted that the OXA-410 protein ([KJ584919](#)) had an adenine insertion at bp 820, leading to the

modification of the last amino acid (L274Y) and the addition of 4 supplementary amino acids. The OXA-409 protein ([KJ584918](#)) had an insertion of a cysteine at amino acid position 19. The new enzyme OXA-338 is encoded by two different nucleotide sequences (GenBank accession numbers [KF048909](#) and [KJ584925](#)). Finally, the [KJ584925](#) gene sequence differed from that of [KF048909](#) by 6 synonymous mutations.

Comparison between MLST and *bla_{OXA-51}* typing. Most of the STs described in this study had a specific *bla_{OXA-51}*-like gene variant (Table 2), with the exception of ST216 and ST470, both of which had the *bla_{OXA-51}* variant, and ST295 and ST468, both of which had the *bla_{OXA-344}* variant. Overall, each ST led to a specific OXA protein variant, except ST469 and ST475, both of which had the OXA-71 protein variant; ST1 and ST292, which had the OXA-69 protein variant; and ST118 and ST286, which had the OXA-338 protein variant (Table 2 and Fig. 3).

TABLE 2 Characteristics of the 42 *A. baumannii* isolates identified in this study

No. of isolates	Sample	Origin	City	Sequence type ^a	OXA protein variant ^b
1	Water	Artesian well	Koura	1	OXA-69
1	Feces	Cow	Akkar	10	OXA-68
1	Meat	Cow	Tripoli	13	OXA-346 (KF048919)
2	Feces, water used by animals	Cow (feces)	Akkar	46	OXA-104
2	Water	Sources	Akkar	108	OXA-132
1	Feces	Cow	Sour	118	OXA-338 (KJ584925)
1	Rectum	Cat	Tripoli	138	OXA-64
1	Mouth	Dog	Tripoli	164	OXA-91
1	Milk	Cow	Akkar	193	OXA-120
1	Cheese		Tripoli	216	OXA-51
1	Mouth	Rabbit	Tripoli	221	JX865392.1
1	Mouth	Goat	Tripoli	250	OXA-407 (KJ584916)
2	Meat and mouth	Cow	Tripoli	286	OXA-338 (KF048909)
1	Meat	Cow	Tripoli	287	OXA-106 (KF048910)
1	Feces	Cow	Akkar	288	OXA-339 (KF048911)
1	Feces	Cow	Akkar	289	OXA-337
1	Feces	Cow	Akkar	290	OXA-340 (KF048912)
1	Feces	Cow	Akkar	291	OXA-341 (KF048913)
2	Feces	Cow	Akkar	292	OXA-69 (KF048914)
1	Feces	Cow	Akkar	293	OXA-342 (KF048915)
2	Water, mouth	Artesian well (water) horse (mouth)	Zgharta, Tripoli	294	OXA-343 (KF048916)
1	Cheese		Tripoli	295	OXA-344 (KF048917)
1	Meat	Cow	Tripoli	296	OXA-345 (KF048918)
1	Rectum	Chicken	Tripoli	464	OXA-94
1	Rectum	Dog	Zgharta	465	OXA-408 (KJ584917)
1	Rectum	Cow	Zgharta	466	OXA-409 (KJ584918)
1	Rectum	Dog	Zgharta	467	OXA-410 (KJ584919)
1	Rectum	Cat	Tripoli	468	OXA-344 (KF048917)
2	Mouth	Cow and goat	Tripoli, El Denieh	469	OXA-71
1	Mouth	Cow	Tripoli	470	OXA-51
1	Mouth	Cow	Tripoli	471	OXA-411 (KJ584920)
1	Feces	Mule	Akkar	472	OXA67
1	Feces	Cow	Akkar	473	OXA-412 (KJ584921)
1	Feces	Cow	Akkar	474	OXA-413 (KJ584922)
1	Feces	Donkey	Akkar	475	OXA-71 (KJ584923)
1	Feces	Goat	Akkar	476	OXA-65 (KJ584924)

^a The novel STs found in this study are in boldface.

^b OXA-51 protein variants found for the first time in this study. GenBank accession numbers are provided in parentheses for new *bla*_{OXA-51} gene variants described for the first time in this study.

DISCUSSION

Although the ubiquitous existence of *A. baumannii* in nature has been considered a common misconception by some authors (7), several recent studies have undeniably highlighted the presence of extrahospital reservoirs (9, 22, 30, 31, 33). These observations have mainly been made through recent implementation of molecular methods, such as *bla*_{OXA-51}-like PCR or *rpoB* gene sequencing, improving detection and identification of *A. baumannii* and other species of the genus *Acinetobacter* (42, 48, 49). In our study, we evidenced the extrahospital presence of *A. baumannii* in Lebanon. We showed that 8% of the animals studied carried *A. baumannii* in their flora. These animals lived on farms or were wild animals and had never been in contact with a hospital environment, such as veterinary clinics. *A. baumannii* has previously been documented as an animal colonizer with different prevalences in different countries: in Senegal, 5.1% (20); in Scotland, 1.2% (30); and on La Reunion Island, 6.5% (31). We have also found the

bacterium in food produced from animals, such as cow meat, raw cheese, and raw milk, reinforcing the idea that animals could be a potential reservoir of *A. baumannii*. Additionally, we have isolated the bacterium from water samples, while all the soil samples tested were negative. Two hypotheses can arise from the detection of *A. baumannii* in water: that water is a normal habitat of *A. baumannii* or that the presence of the bacterium results from human or animal contamination. We cannot exclude either of these hypotheses, but the detection of a novel ST (ST294) in a horse's mouth, as well as in an artesian well, could support the second hypothesis.

We have studied the *A. baumannii* population structure by MLST typing, which is considered a gold standard and is intensively applied in the characterization of genotypes circulating in hospitals. The current MLST-based global population structure is formed by 26 clones divided into 18 international clones and 8 European- or Asian-restricted clones (2). However, it is evident that there are no sufficient data regarding genotypes of isolates




FIG 2 Population snapshot determined by eBURST analysis of 587 sequences present in the MLST Pasteur database (last update, 8 July 2014). The dots represent STs. The STs identified in this study are shown next to their corresponding dots. Boldface indicates a new ST described in this study. The large circles indicate that our identified ST belonged to a clonal complex, whose name is shown next to the circle.

isolated outside hospitals. Improving the MLST database with extrahospital *A. baumannii* genotypes could be important, since it may improve our understanding of the potential reservoirs, the origins of human infections, and the acquisition of resistance mechanisms in the species. In our study, we identified 36 STs of *A. baumannii*; some were identical to those isolated in human infections, and 24 were new genotypes never reported previously. They were all found in animals or in animal-derived food and showed huge diversity in population structures. This diversity was not in accordance with the findings of Hamouda et al. (30), who found only 4 different genotypes in the isolates recovered from cattle and pigs in their study, and the results of Belmonte et al. (31), who revealed the presence of a single pulsed-field gel electrophoresis (PFGE) genotype/ST25 in pets recovered from geographically distant veterinary clinics on La Reunion Island.

The bla_{OXA-51} gene is an intrinsic carbapenemase gene specific to *A. baumannii* and is regarded as a tool for *A. baumannii* identification (50). Analysis of our 42 *A. baumannii* isolates allowed the identification of 34 bla_{OXA-51} gene variants. Among them, 21 were new. These 21 sequences were all associated with animal origins, showing a potentially huge diversity in the *A. baumannii* population. These observations have previously been made by Hamouda et al., who reported three new $bla_{OXA-148}$, $bla_{OXA-149}$, and $bla_{OXA-150}$ variants in cattle in Scotland (30). In addition, our results illustrate the usefulness of bla_{OXA-51} as a single-locus-based typing method (51). We observed good correlation between

MLST and bla_{OXA-51} typing, since each bla_{OXA-51} like gene variant had its specific ST, with two exceptions: ST216 and ST470, which had the same bla_{OXA-51} gene, and ST295 and ST468, which had the same $bla_{OXA-344}$ gene. Our bla_{OXA-51} gene-sequencing results were concordant with the worldwide MLST results reported in other studies, such as bla_{OXA-69} usually being associated with ST1 (51), $bla_{OXA-120}$ with ST193 (52), bla_{OXA-68} with ST10 (3, 53), and bla_{OXA-94} with ST85 (15). Finally, some bla_{OXA-51} variants found in our new STs have previously been described in human STs. Thus, bla_{OXA-71} , detected in our ST469 *A. baumannii* isolate, has been described in the international clone 3 (51). Similarly, bla_{OXA-64} , previously reported in ST25 (51), has been found in ST138. It is interesting that ST138 is a trilocus variant of ST25.

Analysis of the antibiotic susceptibility results showed that a susceptible *A. baumannii* population prevailed outside hospitals in Lebanon. The majority of the isolates (40/42) lacked *ISAbal*, an insertion sequence that is considered the first step in resistance evolution in *A. baumannii* (54). However, we identified a $bla_{OXA-143}$ gene in an *A. baumannii* isolate from a horse, as well as a bla_{OXA-24} gene in an *A. pittii* isolate from a rabbit. These results highlight the potential presence of reservoirs of resistance genes in the environment. The $bla_{OXA-143}$ gene has recently been detected and reported only in Brazil and South Korea (50). Until now, most of the *A. baumannii* populations detected outside hospitals were susceptible to antibiotics (21, 27, 30–32). However, there have been growing concerns after the description of a bla_{OXA-23} gene from




FIG 3 Maximum-likelihood nucleotide tree of 35 *bla*_{OXA-51}-like genes. These 35 genes correspond to 34 *bla*_{OXA-51} variants identified in this study and the *bla*_{OXA-66} gene (the *bla*_{OXA-51} representative of clonal complex 2). MEGA 6 was used to build the phylogenetic tree. Bootstrap values are shown at the nodes. One thousand replicates were used to calculate the bootstrap values.

human stool and lice in Senegal (20); NDM-1-producing *A. baumannii* tk;4 from a pig in China (55); and other carbapenemase-producing *Acinetobacter* spp. from pets, food, and their environments (56).

One other important finding in our study is the identifica-

tion of 30 isolates with low levels of nucleotide homology with all available described *Acinetobacter* species, which are assumed to be putative novel species. These observations show the species diversity of environmental isolates within the genus *Acinetobacter*. Several publications have described new isolates (22, 36, 57),




FIG 4 Amino acid sequence alignment of the 16 new OXA-51-like proteins detected in this study and of OXA-51 (the founding member of OXA-51-like beta-lactamases), OXA-66 (an OXA-51 representative variant of CC2), OXA-69 (an OXA-51 representative variant of CC1), and OXA-71 (an OXA-51 representative variant of CC3) (52). Protein accession numbers: OXA-51, WP_002033109.1; OXA-66, YP_001846219.1; OXA-69, YP_001713983.1; and OXA-71, WP_001021785.1.

which indicates that our knowledge of the genus *Acinetobacter* is still evolving.

In conclusion, our paper reports the occurrence of *A. baumannii* isolates outside Lebanese hospitals and is one of a limited number of worldwide studies exploring the population in the environment, food, and animals. Detection of successful human genotypes, such as international clones 1 and 10, in water and animals is a worrying issue for public health. Furthermore, the roles of newly identified animal clones and their involvement in human diseases, especially in community-acquired infections, should be investigated. Our findings suggest that animals could be a potential reservoir for *A. baumannii* and the spread of new, emerging carbapenemase genes, such as *bla*_{OXA-143}, to humans. Additional large epidemiological studies are required to confirm the significance of our primary results and to determine the real distribution of these clones in Lebanon and the possible interactions between the different environments.

ACKNOWLEDGMENTS

We thank the team of curators of the Institut Pasteur MLST databases for curating the data and making them publicly available at <http://bigsdh.web.pasteur.fr/>. We also thank Taha Abdo, Mariam Yehya, Farah Obeid Charouf, Imane Darwich, Husam Khaled, and Catherine Quinqueneau for their excellent technical assistance. We are very grateful to our colleagues Dima Safadi and Marwan Osman and the veterinary doctors Rabah Outour, Rami El Rifi, and Kamal Mesto for their assistance in sampling.

We have no conflicts of interest.

This work was supported by the AZM Research Center for Biotechnology and its Application, Lebanese University, Tripoli, Lebanon.

REFERENCES

1. Kempf M, Rolain J-M. 2012. Emergence of resistance to carbapenems in *Acinetobacter baumannii* in Europe: clinical impact and therapeutic options. *Int J Antimicrob Agents* 39:105–114. <http://dx.doi.org/10.1016/j.ijantimicag.2011.10.004>.
2. Karah N, Sundsfjord A, Towner K, Samuelsen Ø. 2012. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of *Acinetobacter baumannii*. *Drug Resist Updat* 15:237–247. <http://dx.doi.org/10.1016/j.drug.2012.06.001>.
3. Zarrilli R, Pournaras S, Giannouli M, Tsakris A. 2013. Global evolution of multidrug-resistant *Acinetobacter baumannii* clonal lineages. *Int J Antimicrob Agents* 41:11–19. <http://dx.doi.org/10.1016/j.ijantimicag.2012.09.008>.
4. Dijkshoorn L, Aucken H, Gerner-Smidt P, Janssen P, Kaufmann M, Garaizar J, Ursing J, Pitt T. 1996. Comparison of outbreak and nonoutbreak *Acinetobacter baumannii* strains by genotypic and phenotypic methods. *J Clin Microbiol* 34:1519–1525.
5. Diancourt L, Passet V, Nemec A, Dijkshoorn L, Brisse S. 2010. The population structure of *Acinetobacter baumannii*: expanding multiresistant clones from an ancestral susceptible genetic pool. *PLoS One* 5:e10034. <http://dx.doi.org/10.1371/journal.pone.0010034>.
6. Higgins Dammhayn C, Hackel M, Seifert H. 2010. Global spread of carbapenem-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother* 65:233–238. <http://dx.doi.org/10.1093/jac/dkp428>.
7. Towner KJ. 2009. *Acinetobacter*: an old friend, but a new enemy. *J Hosp Infect* 73:355–363. <http://dx.doi.org/10.1016/j.jhin.2009.03.032>.
8. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospi-

- tals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 5:939–951. <http://dx.doi.org/10.1038/nrmicro1789>.
9. Eveillard M, Kempf M, Belmonte O, Pailhoriès H, Joly-Guillou M-L. 2013. Reservoirs of *Acinetobacter baumannii* outside the hospital and potential involvement in emerging human community-acquired infections. *Int J Infect Dis* 17:e802–e805. <http://dx.doi.org/10.1016/j.ijid.2013.03.021>.
 10. Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. 2007. Community-acquired *Acinetobacter* infections. *Eur J Clin Microbiol Infect Dis* 26:857–868. <http://dx.doi.org/10.1007/s10096-007-0365-6>.
 11. Ong CWM, Lye DCB, Khoo KL, Chua GSW, Yeoh SF, Leo YS, Tambyah PA, Chua AC. 2009. Severe community-acquired *Acinetobacter baumannii* pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific. *Respirology* 14:1200–1205. <http://dx.doi.org/10.1111/j.1440-1843.2009.01630.x>.
 12. Wang Y, Hao P, Lu B, Yu H, Huang W, Hou H, Dai K. 2010. Causes of infection after earthquake, China, 2008. *Emerg Infect Dis* 16:974–975. <http://dx.doi.org/10.3201/eid1606.091523>.
 13. Uçkay I, Sax H, Harbarth S, Bernard L, Pittet D. 2008. Multi-resistant infections in repatriated patients after natural disasters: lessons learned from the 2004 tsunami for hospital infection control. *J Hosp Infect* 68: 1–8. <http://dx.doi.org/10.1016/j.jhin.2007.10.018>.
 14. Sheppard FR, Keiser P, Craft DW, Gage F, Robson M, Brown TS, Petersen K, Sincock S, Kasper M, Hawksworth J, Tadaki D, Davis TA, Stojadinovic A, Elster E. 2010. The majority of US combat casualty soft-tissue wounds are not infected or colonized upon arrival or during treatment at a continental US military medical facility. *Am J Surg* 200: 489–495. <http://dx.doi.org/10.1016/j.amjsurg.2010.03.001>.
 15. Rafei R, Dabboussi F, Hamze M, Eveillard M, Lemarié C, Mallat H, Rolain J-M, Joly-Guillou M-L, Kempf M. 2014. First report of blaNDM-1-producing *Acinetobacter baumannii* isolated in Lebanon from civilians wounded during the Syrian war. *Int J Infect Dis* 21:21–23. <http://dx.doi.org/10.1016/j.ijid.2014.01.004>.
 16. Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vanechoutte M. 1997. Distribution of *Acinetobacter* species on human skin: comparison of phenotypic and genotypic identification methods. *J Clin Microbiol* 35:2819–2825.
 17. Berlau J, Aucken H, Malnick H, Pitt T. 1999. Distribution of *Acinetobacter* species on skin of healthy humans. *Eur J Clin Microbiol Infect Dis* 18:179–183. <http://dx.doi.org/10.1007/s100960050254>.
 18. Dijkshoorn L, van Aken E, Shunburne L, van der Reijden TJK, Bernards AT, Nemeč A, Towner KJ. 2005. Prevalence of *Acinetobacter baumannii* and other *Acinetobacter* spp. in faecal samples from non-hospitalised individuals. *Clin Microbiol Infect* 11:329–332. <http://dx.doi.org/10.1111/j.1469-0691.2005.01093.x>.
 19. Chu YW, Leung CM, Houang ET, Ng KC, Leung CB, Leung HY, Cheng AF. 1999. Skin carriage of acinetobacters in Hong Kong. *J Clin Microbiol* 37:2962–2967.
 20. Kempf M, Rolain J-M, Diatta G, Azza S, Samb B, Mediannikov O, Gassama Sow A, Diene SM, Fenollar F, Raoult D. 2012. Carbapenem resistance and *Acinetobacter baumannii* in Senegal: the paradigm of a common phenomenon in natural reservoirs. *PLoS One* 7:e39495. <http://dx.doi.org/10.1371/journal.pone.0039495>.
 21. Zeana C, Larson E, Sahni J, Bayuga SJ, Wu F, Della-Latta P. 2003. The epidemiology of multidrug-resistant *Acinetobacter baumannii*: does the community represent a reservoir? *Infect Control Hosp Epidemiol* 24:275–279. <http://dx.doi.org/10.1086/502209>.
 22. Houang ET, Chu YW, Leung CM, Chu KY, Berlau J, Ng KC, Cheng AF. 2001. Epidemiology and infection control implications of *Acinetobacter* spp. in Hong Kong. *J Clin Microbiol* 39:228–234. <http://dx.doi.org/10.1128/JCM.39.1.228-234.2001>.
 23. Vangnai AS, Petchkroh W. 2007. Biodegradation of 4-chloroaniline by bacteria enriched from soil. *FEMS Microbiol Lett* 268:209–216. <http://dx.doi.org/10.1111/j.1574-6968.2006.00579.x>.
 24. Guardabassi L, Dalsgaard A, Olsen JE. 1999. Phenotypic characterization and antibiotic resistance of *Acinetobacter* spp. isolated from aquatic sources. *J Appl Microbiol* 87:659–667. <http://dx.doi.org/10.1046/j.1365-2672.1999.00905.x>.
 25. Huys G, Bartie K, Cnockaert M, Hoang Oanh DT, Phuong NT, Somsiri T, Chinabut S, Yusoff FM, Shariff M, Giacomini M, Teale A, Swings J. 2007. Biodiversity of chloramphenicol-resistant mesophilic heterotrophs from Southeast Asian aquaculture environments. *Res Microbiol* 158:228–235. <http://dx.doi.org/10.1016/j.resmic.2006.12.011>.
 26. Berlau J, Aucken H, Houang E, Pitt TL. 1999. Isolation of *Acinetobacter* spp including *A. baumannii* from vegetables: implications for hospital-acquired infections. *J Hosp Infect* 42:201–204. <http://dx.doi.org/10.1053/jhin.1999.0602>.
 27. Gurung M, Nam HM, Tamang MD, Chae MH, Jang GC, Jung SC, Lim SK. 2013. Prevalence and antimicrobial susceptibility of *Acinetobacter* from raw bulk tank milk in Korea. *J Dairy Sci* 96:1997–2002. <http://dx.doi.org/10.3168/jds.2012-5965>.
 28. Zordan S, Prenger-Berninghoff E, Weiss R, van der Reijden T, van den Broek P, Baljer G, Dijkshoorn L. 2011. Multidrug-resistant *Acinetobacter baumannii* in veterinary clinics, Germany. *Emerg Infect Dis* 17:1751–1754. <http://dx.doi.org/10.3201/eid1709.101931>.
 29. Endimiani A, Hujer KM, Hujer AM, Bertschy I, Rossano A, Koch C, Gerber V, Francey T, Bonomo RA, Perretter V. 2011. *Acinetobacter baumannii* isolates from pets and horses in Switzerland: molecular characterization and clinical data. *J Antimicrob Chemother* 66:2248–2254. <http://dx.doi.org/10.1093/jac/dkr289>.
 30. Hamouda A, Findlay J, Al Hassan L, Amyes SGB. 2011. Epidemiology of *Acinetobacter baumannii* of animal origin. *Int J Antimicrob Agents* 38: 314–318. <http://dx.doi.org/10.1016/j.ijantimicag.2011.06.007>.
 31. Belmonte O, Pailhoriès H, Kempf M, Gaultier MP, Lemarié C, Ramont C, Joly-Guillou ML, Eveillard M. 2014. High prevalence of closely-related *Acinetobacter baumannii* in pets according to a multicentre study in veterinary clinics, Reunion Island. *Vet Microbiol* 170:446–450. <http://dx.doi.org/10.1016/j.vetmic.2014.01.042>.
 32. La Scola B, Raoult D. 2004. *Acinetobacter baumannii* in human body louse. *Emerg Infect Dis* 10:1671–1673. <http://dx.doi.org/10.3201/eid1009.040242>.
 33. Kempf M, Abdissa A, Diatta G, Trape J-F, Angelakis E, Mediannikov O, La Scola B, Raoult D. 2012. Detection of *Acinetobacter baumannii* in human head and body lice from Ethiopia and identification of new genotypes. *Int J Infect Dis* 16:e680–e683. <http://dx.doi.org/10.1016/j.ijid.2012.05.1024>.
 34. Bouvresse S, Socolovshi C, Berdjane Z, Durand R, Izri A, Raoult D, Chosidow O, Brouqui P. 2011. No evidence of *Bartonella quintana* but detection of *Acinetobacter baumannii* in head lice from elementary school-children in Paris. *Comp Immunol Microbiol Infect Dis* 34:475–477. <http://dx.doi.org/10.1016/j.cimid.2011.08.007>.
 35. Gouveia C, Asensi MD, Zahner V, Rangel EF, Oliveira SM. 2008. Study on the bacterial midgut microbiota associated to different Brazilian populations of *Lutzomyia longipalpis* (Lutz & Neiva) (Diptera: Psychodidae). *Neotrop Entomol* 37:597–601. <http://dx.doi.org/10.1590/S1519-566X2008000500016>.
 36. Choi J-Y, Kim Y, Ko EA, Park YK, Jheong W-H, Ko G, Ko KS. 2012. *Acinetobacter* species isolates from a range of environments: species survey and observations of antimicrobial resistance. *Diagn Microbiol Infect Dis* 74:177–180. <http://dx.doi.org/10.1016/j.diagmicrobio.2012.06.023>.
 37. Rose M, Landman D, Quale J. 2014. Are community environmental surfaces near hospitals reservoirs for gram-negative nosocomial pathogens? *Am J Infect Control* 42:346–348. <http://dx.doi.org/10.1016/j.ajic.2013.12.025>.
 38. Zarrilli R, Vitale D, Di Popolo A, Bagattini M, Daoud Z, Khan AU, Affi C, Triassi M. 2008. A plasmid-borne blaOXA-58 gene confers imipenem resistance to *Acinetobacter baumannii* isolates from a Lebanese hospital. *Antimicrob Agents Chemother* 52:4115–4120. <http://dx.doi.org/10.1128/AAC.00366-08>.
 39. Di Popolo A, Giannouli M, Triassi M, Brisse S, Zarrilli R. 2011. Molecular epidemiological investigation of multidrug-resistant *Acinetobacter baumannii* strains in four Mediterranean countries with a multilocus sequence typing scheme. *Clin Microbiol Infect* 17:197–201. <http://dx.doi.org/10.1111/j.1469-0691.2010.03254.x>.
 40. Giannouli M, Tomasone F, Agodi A, Vahaboglu H, Daoud Z, Triassi M, Tsakris A, Zarrilli R. 2009. Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* strains in intensive care units of multiple Mediterranean hospitals. *J Antimicrob Chemother* 63:828–830. <http://dx.doi.org/10.1093/jac/dkp032>.
 41. Baumann P. 1968. Isolation of *Acinetobacter* from soil and water. *J Bacteriol* 96:39–42.
 42. Gundi VAKB, Dijkshoorn L, Burignat S, Raoult D, La Scola B. 2009. Validation of partial *rpoB* gene sequence analysis for the identification of clinically important and emerging *Acinetobacter* species. *Microbiology* 155:2333–2341. <http://dx.doi.org/10.1099/mic.0.026054-0>.
 43. Mesli E, Berrazeg M, Drissi M, Bekkhoucha SN, Rolain JM. 2013. Prevalence of carbapenemase-encoding genes including New Delhi metal-

- lo- β -lactamase in *Acinetobacter* species, Algeria. *Int J Infect Dis* 17:e739–e743. <http://dx.doi.org/10.1016/j.ijid.2013.02.024>.
44. Higgins PG, Lehmann M, Seifert H. 2010. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int J Antimicrob Agents* 35:305–314. <http://dx.doi.org/10.1016/j.ijantimicag.2009.10.014>.
 45. Ruiz M, Marti S, Fernandez-Cuenca F, Pascual A, Vila J. 2007. Prevalence of IS(Aba1) in epidemiologically unrelated *Acinetobacter baumannii* clinical isolates. *Clin Microbiol Infect* 13:1192–1198. <http://dx.doi.org/10.1111/j.1469-0691.2007.01825.x>.
 46. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG. 2004. eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. *J Bacteriol* 186:1518–1530. <http://dx.doi.org/10.1128/JB.186.5.1518-1530.2004>.
 47. Hamouda A, Evans BA, Townner KJ, Amyes SGB. 2010. Characterization of epidemiologically unrelated *Acinetobacter baumannii* isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of blaOXA-51-like genes. *J Clin Microbiol* 48:2476–2483. <http://dx.doi.org/10.1128/JCM.02431-09>.
 48. La Scola B, Gundi VA, Khamis A, Raoult D. 2006. Sequencing of the *rpoB* gene and flanking spacers for molecular identification of *Acinetobacter* species. *J Clin Microbiol* 44:827–832. <http://dx.doi.org/10.1128/JCM.44.3.827-832.2006>.
 49. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. 2006. Identification of *Acinetobacter baumannii* by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol* 44:2974–2976. <http://dx.doi.org/10.1128/JCM.01021-06>.
 50. Evans BA, Amyes SGB. 2014. OXA β -lactamases. *Clin Microbiol Rev* 27:241–263. <http://dx.doi.org/10.1128/CMR.00117-13>.
 51. Pournaras S, Gogou V, Giannouli M, Dimitroulia E, Dafopoulou K, Tsakris A, Zarrilli R. 2014. Single locus sequence-based typing of blaOXA-51-like gene for rapid classification of *Acinetobacter baumannii* clinical isolates to international clones. *J Clin Microbiol* 52:1653–1657. <http://dx.doi.org/10.1128/JCM.03565-13>.
 52. Izdebski R, Fielt J, Hryniewicz W, Gniadkowski M. 2012. Molecular analysis of *Acinetobacter baumannii* isolates from invasive infections in 2009 in Poland. *J Clin Microbiol* 50:3813–3815. <http://dx.doi.org/10.1128/JCM.02271-12>.
 53. Zander E, Nemeč A, Seifert H, Higgins PG. 2012. Association between β -lactamase-encoding bla(OXA-51) variants and DiversiLab rep-PCR-based typing of *Acinetobacter baumannii* isolates. *J Clin Microbiol* 50:1900–1904. <http://dx.doi.org/10.1128/JCM.06462-11>.
 54. Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, Pitt TL. 2006. The role of ISAbal in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. *FEMS Microbiol Lett* 258:72–77. <http://dx.doi.org/10.1111/j.1574-6968.2006.00195.x>.
 55. Zhang W-J, Lu Z, Schwarz S, Zhang R-M, Wang X-M, Si W, Yu S, Chen L, Liu S. 2013. Complete sequence of the bla(NDM-1)-carrying plasmid pNDM-AB from *Acinetobacter baumannii* of food animal origin. *J Antimicrob Chemother* 68:1681–1682. <http://dx.doi.org/10.1093/jac/dkt066>.
 56. Guerra B, Fischer J, Helmuth R. 2014. An emerging public health problem: acquired carbapenemase-producing microorganisms are present in food-producing animals, their environment, companion animals and wild birds. *Vet Microbiol* 171:290–297. <http://dx.doi.org/10.1016/j.vetmic.2014.02.001>.
 57. Kumsa B, Socolovschi C, Parola P, Rolain J-M, Raoult D. 2012. Molecular detection of *Acinetobacter* species in lice and keds of domestic animals in Oromia Regional State, Ethiopia. *PLoS One* 7:e52377. <http://dx.doi.org/10.1371/journal.pone.0052377>.